Recent animal trials predict ability to cut Alzheimer’s, dementia in half
Researchers at the University of Texas Southwestern Medical Center in Dallas said a new experimental Alzheimer's disease vaccine showed promising results during recent testing in mice and are hopeful the vaccine will make it to human trials.
In the animal trials researchers said the experimental vaccine showed it could delay the effects of the degenerative brain disease, according to Newsweek.
The journey from animal tests to human use is long and arduous, and many promising cures do not withstand it. But a senior author of the research published this week in the journal Alzheimer's Research & Therapy told USA Today if the vaccine is proven safe and effective during human trials it could reduce the total number of dementia diagnoses in half.
Alzheimer's disease is the most common cause of dementia, which is the broad term used to describe symptoms of cognitive decline that causes problems with memory, thinking and behavior.
The experimental vaccine could be a monumental push forward in the fight against dementia, with previous Alzheimer's vaccines causing damaging side effects including brain inflammation. Recent tests on monkeys and rabbits found the vaccine works by prompting the body to produce antibodies that reduce the buildup of amyloid and tau. Both proteins are typically indicative of the degenerative brain disease's presence in the body.
Read the full story at Newsweek.
I Advance Senior Care is the industry-leading source for practical, in-depth, business-building, and resident care information for owners, executives, administrators, and directors of nursing at assisted living communities, skilled nursing facilities, post-acute facilities, and continuing care retirement communities. I Advance Senior Care editorial team and industry experts provide market analysis, strategic direction, policy commentary, clinical best-practices, business management, and technology breakthroughs.
Topics: Alzheimer's/Dementia , Uncategorized